[{"id":"5895dd46-f4f2-46c6-9499-4596f2c29417","acronym":"","url":"https://clinicaltrials.gov/study/NCT06011772","created_at":"2023-08-25T15:08:32.780Z","updated_at":"2025-02-25T14:03:46.296Z","phase":"Phase 1","brief_title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06011772","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" KRAS • BRAF • RAS","pipe":" | ","alterations":" BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS • BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 12/04/2023","start_date":" 12/04/2023","primary_txt":" Primary completion: 12/04/2025","primary_completion_date":" 12/04/2025","study_txt":" Completion: 12/04/2026","study_completion_date":" 12/04/2026","last_update_posted":"2025-02-19"},{"id":"743006a6-c939-4023-8010-4e3aee085ae3","acronym":"E7386-J081-102","url":"https://clinicaltrials.gov/study/NCT04008797","created_at":"2022-06-28T02:54:50.954Z","updated_at":"2025-02-25T15:18:13.404Z","phase":"Phase 1/2","brief_title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","source_id_and_acronym":"NCT04008797 - E7386-J081-102","lead_sponsor":"Eisai Inc.","biomarkers":" EGFR • KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Lenvima (lenvatinib) • doxorubicin hydrochloride • E7386"],"overall_status":"Recruiting","enrollment":" Enrollment 301","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-11"},{"id":"83a4cc91-840b-45a5-8084-819f697c1e10","acronym":"CA209-8LC","url":"https://clinicaltrials.gov/study/NCT03711058","created_at":"2021-01-18T18:11:36.282Z","updated_at":"2025-02-25T14:27:43.047Z","phase":"Phase 1/2","brief_title":"Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer","source_id_and_acronym":"NCT03711058 - CA209-8LC","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 06/14/2022","primary_completion_date":" 06/14/2022","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-13"},{"id":"72e4ff17-7877-4262-a51d-7d8c81b8c732","acronym":"Neo ReNi II","url":"https://clinicaltrials.gov/study/NCT05418972","created_at":"2022-06-15T16:54:46.563Z","updated_at":"2025-02-25T14:17:02.671Z","phase":"Phase 2","brief_title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","source_id_and_acronym":"NCT05418972 - Neo ReNi II","lead_sponsor":"Melanoma Institute Australia","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • NRAS mutation • NRAS wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NRAS mutation • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/14/2023","start_date":" 08/14/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2035","study_completion_date":" 12/01/2035","last_update_posted":"2025-01-07"},{"id":"ac4c8720-90f3-4cfe-bd1a-08988315c11c","acronym":"REPROGRAM-01","url":"https://clinicaltrials.gov/study/NCT04534218","created_at":"2021-01-18T21:42:20.525Z","updated_at":"2025-02-25T17:24:47.487Z","phase":"Phase 2","brief_title":"Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04534218 - REPROGRAM-01","lead_sponsor":"Centre Hospitalier Universitaire de Besancon","biomarkers":" KRAS","pipe":" | ","alterations":" RAS wild-type • NRAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • Stivarga (regorafenib) • aspirin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 12/13/2023","primary_completion_date":" 12/13/2023","study_txt":" Completion: 12/13/2023","study_completion_date":" 12/13/2023","last_update_posted":"2024-12-20"},{"id":"76a5691d-3c36-403e-ae0a-2107bdb5f547","acronym":"LEAP-017","url":"https://clinicaltrials.gov/study/NCT04776148","created_at":"2021-03-01T13:52:36.340Z","updated_at":"2025-02-25T13:35:46.773Z","phase":"Phase 3","brief_title":"Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)","source_id_and_acronym":"NCT04776148 - LEAP-017","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 480","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 02/20/2023","primary_completion_date":" 02/20/2023","study_txt":" Completion: 09/27/2024","study_completion_date":" 09/27/2024","last_update_posted":"2024-10-29"},{"id":"285e0fae-6b50-4026-b6af-15e5137223d2","acronym":"ZWI-ZW25-201","url":"https://clinicaltrials.gov/study/NCT03929666","created_at":"2021-01-18T19:21:37.373Z","updated_at":"2024-07-02T16:34:37.769Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","source_id_and_acronym":"NCT03929666 - ZWI-ZW25-201","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2 • KRAS • BRAF • NRAS • RAS","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • gemcitabine • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/29/2019","start_date":" 08/29/2019","primary_txt":" Primary completion: 11/28/2025","primary_completion_date":" 11/28/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-06-06"},{"id":"f7adec30-958d-4721-9a82-00722f4075ec","acronym":"PULSE","url":"https://clinicaltrials.gov/study/NCT03992456","created_at":"2021-01-18T19:37:42.598Z","updated_at":"2024-07-02T16:35:02.247Z","phase":"Phase 2","brief_title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","source_id_and_acronym":"NCT03992456 - PULSE","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type","tags":["EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 10/07/2024","study_completion_date":" 10/07/2024","last_update_posted":"2024-05-21"},{"id":"081658f6-dc5c-4209-b44c-5446bf4825c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03442569","created_at":"2021-01-18T16:58:41.837Z","updated_at":"2025-02-25T14:38:08.450Z","phase":"Phase 2","brief_title":"PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC","source_id_and_acronym":"NCT03442569","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" KRAS • BRAF • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" KRAS wild-type • NRAS wild-type","tags":["KRAS • BRAF • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Vectibix (panitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 09/21/2020","primary_completion_date":" 09/21/2020","study_txt":" Completion: 12/22/2024","study_completion_date":" 12/22/2024","last_update_posted":"2024-05-14"},{"id":"3a511d5d-3245-4fbd-a2c8-a89db4e723ed","acronym":"CIFRA","url":"https://clinicaltrials.gov/study/NCT03874026","created_at":"2021-01-18T19:06:05.689Z","updated_at":"2024-07-02T16:35:12.803Z","phase":"Phase 2","brief_title":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","source_id_and_acronym":"NCT03874026 - CIFRA","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression","tags":["KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/05/2019","start_date":" 09/05/2019","primary_txt":" Primary completion: 05/19/2023","primary_completion_date":" 05/19/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-03-26"},{"id":"939cf6e0-4581-41cd-811a-c9f07aba8b51","acronym":"STRATEGIC-1","url":"https://clinicaltrials.gov/study/NCT01910610","created_at":"2021-01-18T08:36:45.253Z","updated_at":"2024-07-02T16:35:15.367Z","phase":"Phase 3","brief_title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01910610 - STRATEGIC-1","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" NRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type • NRAS wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type • NRAS wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 464","initiation":"Initiation: 10/30/2013","start_date":" 10/30/2013","primary_txt":" Primary completion: 07/13/2023","primary_completion_date":" 07/13/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-11"},{"id":"8a5cdc08-e416-4ef2-acfc-5bff9d7f6057","acronym":"","url":"https://clinicaltrials.gov/study/NCT04923620","created_at":"2021-06-11T18:56:16.398Z","updated_at":"2024-07-02T16:35:17.693Z","phase":"","brief_title":"Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy","source_id_and_acronym":"NCT04923620","lead_sponsor":"Shanghai Minimally Invasive Surgery Center","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF wild-type • NRAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-02-26"},{"id":"9f45cf54-5cc1-4eb7-81d5-5bf377918b4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05673512","created_at":"2023-01-06T15:58:39.959Z","updated_at":"2024-07-02T16:35:18.530Z","phase":"Phase 2/3","brief_title":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05673512","lead_sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","biomarkers":" HER-2 • KRAS • BRAF • NRAS • MSI","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IAH0968"],"overall_status":"Recruiting","enrollment":" Enrollment 279","initiation":"Initiation: 05/12/2023","start_date":" 05/12/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-02-20"},{"id":"e993ce91-2679-4a51-a9c2-2a1e49731991","acronym":"","url":"https://clinicaltrials.gov/study/NCT03845166","created_at":"2021-01-18T18:59:01.227Z","updated_at":"2024-07-02T16:35:18.886Z","phase":"Phase 1","brief_title":"A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors","source_id_and_acronym":"NCT03845166","lead_sponsor":"Exelixis","biomarkers":" HER-2 • KRAS • BRAF • NRAS • MSI","pipe":" | ","alterations":" BRAF V600E • HR positive • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • HR positive • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Bavencio (avelumab) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-02-19"},{"id":"cee8aba7-65f5-4dfb-8178-d79ff5369a64","acronym":"","url":"https://clinicaltrials.gov/study/NCT04999761","created_at":"2021-08-11T15:53:36.773Z","updated_at":"2024-07-02T16:35:19.007Z","phase":"Phase 1","brief_title":"AB122 Platform Study","source_id_and_acronym":"NCT04999761","lead_sponsor":"Taiho Pharmaceutical Co., Ltd.","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Cyramza (ramucirumab) • Lytgobi (futibatinib) • Yutuo (zimberelimab) • Lonsurf (trifluridine/tipiracil) • Jeselhy (pimitespib) • pamufetinib (TAS-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 715","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-02-16"},{"id":"d32a1468-1f32-43bb-a26b-bca539472397","acronym":"REVERCE II","url":"https://clinicaltrials.gov/study/NCT04117945","created_at":"2021-01-18T20:07:37.386Z","updated_at":"2024-07-02T16:35:20.490Z","phase":"Phase 2","brief_title":"Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04117945 - REVERCE II","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF V600E • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 03/03/2020","start_date":" 03/03/2020","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-02-07"},{"id":"a715a28a-a6ae-4908-ad20-b8ddd7c0da88","acronym":"LCCC1717","url":"https://clinicaltrials.gov/study/NCT03446157","created_at":"2021-01-18T16:59:33.811Z","updated_at":"2024-07-02T16:35:21.094Z","phase":"Phase 2","brief_title":"Palbociclib and Cetuximab in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03446157 - LCCC1717","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/13/2018","start_date":" 03/13/2018","primary_txt":" Primary completion: 05/29/2023","primary_completion_date":" 05/29/2023","study_txt":" Completion: 01/26/2026","study_completion_date":" 01/26/2026","last_update_posted":"2024-02-02"},{"id":"8b1ef189-345f-4d0b-8046-65f241c6c7d3","acronym":"CR-SEQUENCE","url":"https://clinicaltrials.gov/study/NCT03635021","created_at":"2021-01-18T17:51:02.237Z","updated_at":"2024-07-02T16:35:24.963Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","source_id_and_acronym":"NCT03635021 - CR-SEQUENCE","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 419","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 06/28/2025","primary_completion_date":" 06/28/2025","study_txt":" Completion: 06/28/2025","study_completion_date":" 06/28/2025","last_update_posted":"2023-12-28"},{"id":"31f0020c-0510-41ca-b50a-168b2e6ddd86","acronym":"","url":"https://clinicaltrials.gov/study/NCT03087071","created_at":"2021-01-18T15:12:32.712Z","updated_at":"2024-07-02T16:35:25.486Z","phase":"Phase 2","brief_title":"Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer","source_id_and_acronym":"NCT03087071","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • NRAS • MAP2K1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type","tags":["KRAS • BRAF • NRAS • MAP2K1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Vectibix (panitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/29/2017","start_date":" 12/29/2017","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2023-12-21"},{"id":"a7939463-add1-4ee1-b7a9-f0a971710d58","acronym":"FIRE-4","url":"https://clinicaltrials.gov/study/NCT02934529","created_at":"2021-01-18T14:24:36.504Z","updated_at":"2024-07-02T16:35:29.178Z","phase":"Phase 3","brief_title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","source_id_and_acronym":"NCT02934529 - FIRE-4","lead_sponsor":"Ludwig-Maximilians - University of Munich","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Stivarga (regorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 673","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-11-15"},{"id":"bacbc0ce-bbbb-414c-9d75-d5a73ab0532d","acronym":"PARADIGM","url":"https://clinicaltrials.gov/study/NCT02394795","created_at":"2021-01-18T11:25:23.628Z","updated_at":"2024-07-02T16:35:30.810Z","phase":"Phase 3","brief_title":"Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC","source_id_and_acronym":"NCT02394795 - PARADIGM","lead_sponsor":"Takeda","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 823","initiation":"Initiation: 05/29/2015","start_date":" 05/29/2015","primary_txt":" Primary completion: 01/14/2022","primary_completion_date":" 01/14/2022","study_txt":" Completion: 01/14/2022","study_completion_date":" 01/14/2022","last_update_posted":"2023-11-01"},{"id":"54aab516-bbb7-4fbe-9ae9-1df4dc221ac1","acronym":"AVETRIC","url":"https://clinicaltrials.gov/study/NCT04513951","created_at":"2021-01-18T21:38:00.940Z","updated_at":"2024-07-02T16:35:37.436Z","phase":"Phase 2","brief_title":"AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT04513951 - AVETRIC","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS wild-type • NRAS wild-type","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Bavencio (avelumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/01/2020","start_date":" 04/01/2020","primary_txt":" Primary completion: 06/28/2023","primary_completion_date":" 06/28/2023","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2023-09-12"},{"id":"cd56cf4d-3c31-4526-adbd-cc60f37646ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT05774964","created_at":"2023-03-20T20:03:21.979Z","updated_at":"2024-07-02T16:35:52.913Z","phase":"Phase 2","brief_title":"Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases","source_id_and_acronym":"NCT05774964","lead_sponsor":"Liaoning Tumor Hospital \u0026 Institute","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF mutation • KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 03/15/2025","study_completion_date":" 03/15/2025","last_update_posted":"2023-03-20"},{"id":"1e5349cb-f725-41e0-8ace-3958da11d8bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05771181","created_at":"2023-03-16T14:02:31.508Z","updated_at":"2024-07-02T16:35:53.141Z","phase":"Phase 2","brief_title":"Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT05771181","lead_sponsor":"Fudan University","biomarkers":" PD-L1 • KRAS • BRAF • MSI","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["PD-L1 • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2023-03-16"}]